Lexeo Therapeutics, Inc.’s (NASDAQ:LXEO) Lock-Up Period Set To End on May 1st

Posted by Casey Walker on Apr 24th, 2024

Lexeo Therapeutics’ (NASDAQ:LXEO – Get Free Report) lock-up period will expire on Wednesday, May 1st. Lexeo Therapeutics had issued 9,090,910 shares in its IPO on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. After the end of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Lexeo Therapeutics Stock Performance

LXEO stock opened at $12.14 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.21. Lexeo Therapeutics has a twelve month low of $9.00 and a twelve month high of $22.33. The firm has a 50 day moving average of $14.48.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last released its quarterly earnings results on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15). As a group, equities analysts predict that Lexeo Therapeutics will post -3.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Eventide Asset Management LLC bought a new stake in Lexeo Therapeutics in the 4th quarter worth about $40,298,000. Omega Fund Management LLC bought a new position in shares of Lexeo Therapeutics during the 4th quarter worth approximately $28,955,000. Finally, Blackstone Inc. purchased a new position in shares of Lexeo Therapeutics in the 4th quarter worth approximately $9,342,000. 60.67% of the stock is owned by institutional investors.

Lexeo Therapeutics Company Profile

(Get Free Report)

Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.